# Physitrack reports 8% revenue growth and profitable Q2 2026

- Link: https://www.directorstalkinterviews.com/physitrack-reports-8-revenue-growth-and-profitable-q2-2026/4121261071
- Published: 2026-08-24T13:49:53+01:00
- Author: Amilia Stone

**[Physitrack Plc](https://www.directorstalkinterviews.com/company/physitrack-plc/ptrk.st)**(
PTRK.ST), listed on Nasdaq First North Growth Market has published its Q2 2026 report.

**London July 21, 2026, 08:00 CET**

**Group Financial Summary**

| **Metric** | **Q2 2026** | **Q2 2025** | **YoY ∆** | **YtD 2026** | **YtD 2025** | **YoY ∆** | 
| Revenue (€m) (Reported) | 3.4 | 3.2 | 8% | 6.7 | 6.3 | 5% | 
| Constant currency revenue (€m) | 3.4 | 3.2 | 7% | 6.8 | 6.3 | 7% | 
| EBITDA (€m) | 1.1 | 1.0 | 13% | 2.1 | 1.7 | 20% | 
| Adj. EBITDA (€m) | 1.2 | 1.2 | -3% | 2.3 | 2.3 | -3% | 
| EBITDA – CapEx (€m) | 0.3 | 0.4 | -21% | 0.5 | 0.4 | 8% | 
| Adj. EBITDA – CapEx (€m) | 0.3 | 0.6 | -43% | 0.6 | 1.0 | -37% | 
| Operating Cash Flow (continuing operations) (€m) | 0.7 | 0.8 | -14% | 1.6 | 1.8 | -11% | 
| Free Cash Flow (continuing operations) (€m) | (0.2) | 0.1 | -427% | (0.2) | 0.2 | -176% | 
| Free Cash Flow (€m) (continuing operations) exc Legal Settlement | 0.1 | 0.1 | 43% | 0.2 | 0.2 | -34% | 
| Net Profit / (loss) After Tax (€m) | 0.0 | (0.1) | 150% | 0.1 | (0.5) | 123% | 
| ARR per Employee | 410,183 | 190,667 | 115% | 451,201 | 230,808 | 96% |

**Summary for the period**

**Second quarter: 1 April – 30 June 2026**

Based on Alternative Key Performance Measures, the Company’s key financial highlights
for the period are summarised below.

 * Constant currency revenue amounted to EUR 3.4m (EUR 3.2m), corresponding to 7
   per cent year-on-year growth.
 * Subscription revenue continued to represent the majority of Group revenue (96
   per cent), reflecting the strength of the recurring SaaS model.
 * Adjusted EBITDA decreased 3 per cent maintaining at EUR 1.2m (EUR 1.2m), corresponding
   to a margin of 34 per cent (38 per cent).
 * Adjusted EBITDA less CapEx decreases to EUR 0.3m (EUR 0.6m) following heavier
   investment for the targeted US expansion.
 * Operating cash flow from continuing operations maintained at a relatively consistent
   level EUR 0.7m (EUR 0.8m).
 * Free cash flow from continuing operations remained positive at EUR 0.1m (EUR 
   0.1m), maintaining 7 consecutive quarters of positive free cash flow, when adjusting
   for legal matter settlement of €343k dating back to 2018. No further exposure
   remains. This removes historic, non-recurring items to provide a more meaningful
   view of underlying operational cash generation.

**Summary for the full year**

**Second quarter: 1 January – 30 June 2026**

Based on Alternative Key Performance Measures, the Company’s key financial highlights
for the period are summarised below.

 * Measured against Q4 2025, revenue has grown 10% in just six months, demonstrating
   strong underlying momentum in our recurring subscription model.
 * Constant currency revenue amounted to EUR 6.8m (EUR 6.3m), corresponding to 7
   per cent year-on-year growth.
 * Subscription revenue continued to represent the majority of Group revenue (96
   per cent), reflecting the strength of the recurring SaaS model.
 * Adjusted EBITDA decreased 3 per cent maintaining at EUR 2.3m (EUR 2.3m), corresponding
   to a margin of 34 per cent (37 per cent).
 * Adjusted EBITDA less CapEx decreases to EUR 0.6m (EUR 1.0m).
 * Operating cash flow from continuing operations has seen a small decline at EUR
   1.6m (EUR 1.8m) following a turbulent foreign exchange market and fluctuations
   in working capital.
 * Free cash flow from continuing operations remained positive at EUR 0.2m (EUR 
   0.2m), maintaining 7 consecutive quarters of positive free cash flow with the
   above noted adjustment for legal matters now fully settled.

**CEO comment**

Q2 2026 marked another quarter of profitable growth and disciplined execution for
Physitrack. Revenue increased 8 per cent year-on-year to EUR 3.4m and 6 per cent
quarter-on-quarter, taking growth to 10 per cent over the six months since Q4 2025.
Adjusted EBITDA amounted to EUR 1.2m at a margin of 34 per cent, while the Group
delivered its seventh consecutive quarter of positive operating cash flow and returned
to net profit from continuing operations.

Lifecare continued to strengthen, with double-digit revenue growth, higher ARR and
clear evidence of pricing power following the successful implementation of our annual
price increase. Wellness also continued its transformation, delivering a 32 per 
cent adjusted EBITDA margin while progressing its transition towards a more focused
and scalable enterprise SaaS model.

A major milestone during the quarter was the commercial launch of our Remote Therapeutic
Monitoring platform in the United States, with the first paying customers now live.
RTM introduces a new usage-based revenue stream alongside our subscription model
and strengthens our proposition to US clinics by helping them generate reimbursement
revenue through the Physitrack platform. We also achieved US medical device status,
signed agreements with two of the largest hospital providers in the United Kingdom
and continued to participate in some of the largest tenders in the Company’s history
across Europe and the United States.

Alongside these results, we announced a share buyback program and a new long-term
incentive plan for management. The plan will be funded entirely through shares repurchased
into treasury, ensuring that management incentives are aligned with long-term shareholder
value without issuing new shares or diluting existing shareholders. The buyback 
will commence in August 2026.

Our priorities for the remainder of 2026 are clear: convert our North American commercial
momentum into revenue, scale RTM adoption through practitioner education, advance
our AI and motion-capture capabilities, and complete the Wellness enterprise transition
while maintaining the profitability and cash discipline established over recent 
quarters.

Henrik Molin
CEO and Founder

**Lifecare division**

Q2 2026 revenue increased 11 per cent year-on-year to EUR 3.1m, with SaaS revenue
increasing 13 per cent and representing 96 per cent of divisional revenue. ARR reached
EUR 12.7m, an increase of 7 per cent year-on-year and 8 per cent quarter-on-quarter.

ARPL increased 10 per cent year-on-year to EUR 189 following the Group’s annual 
price increase, while average monthly churn remained stable at 1.0 per cent. The
licence base also returned to growth during the quarter, demonstrating that the 
business has absorbed the customer loss reported in Q1 while replacing licences 
at materially higher price points.

SaaS gross margin improved to 90.9 per cent, and adjusted EBITDA increased 11 per
cent year-on-year to EUR 1.6m, corresponding to a margin of 50 per cent. Adjusted
EBITDA less CapEx amounted to EUR 0.8m, reflecting continued investment in the platform,
RTM and the Group’s competitive offering for the US market.

Lifecare continues to provide a high-quality, recurring revenue base with strong
margins, low churn and demonstrated pricing power. The launch of RTM adds a significant
new growth opportunity, particularly in North America, while the division’s established
clinical workflows and integrations continue to support strong customer retention.

**Wellness division**

Q2 2026 revenue amounted to EUR 0.3m, representing a decrease of 14 per cent year-
on-year following the planned expiry of legacy founder-linked contracts, but an 
increase of 3 per cent compared with Q1 2026. ARR reached EUR 0.9m, increasing slightly
quarter-on-quarter as the division continued its transition towards higher-value
enterprise relationships.

ARPL increased 18 per cent year-on-year to EUR 13, reflecting the continued shift
towards larger and more scalable enterprise customers. Customer economics also improved
during the quarter, with churn reducing to 3.7 per cent from 4.5 per cent in Q1 
and NRR increasing to 95.9 per cent.

Adjusted EBITDA increased to EUR 0.1m from broadly breakeven in the corresponding
period last year, representing a margin of 32 per cent. This improvement reflects
the benefits of the restructuring undertaken across the division and demonstrates
that Wellness can operate profitably while completing its portfolio transition.

The division is now focused on building a scalable enterprise SaaS business centred
on Champion Health’s differentiated combination of mental health and musculoskeletal
support. Recently announced customer wins and the introduction of a lower-cost assessment
product provide additional routes to acquire enterprise customers and support a 
land-and-expand commercial model.

**Outlook**

Physitrack enters the second half of 2026 with a focused growth agenda and a stronger
commercial and product foundation. RTM is now live in the United States and is expected
to build progressively over the next 12 to 24 months as practitioner awareness increases
and the product becomes embedded within clinical workflows.

The Group will continue to convert its investment in North America into revenue,
progress its enterprise tender pipeline across Europe and the United States, and
build on the pricing power demonstrated within Lifecare. Product investment will
remain focused on motion capture, AI-enabled development and the Group’s proprietary
clinical data, with the objective of shortening the cycle from identifying market
opportunities to launching monetised products.

Within Wellness, the priority remains replacing expiring legacy contracts with higher-
value enterprise relationships while protecting the profitability achieved following
the restructuring. Across the Group, management will maintain disciplined capital
allocation, execute the announced share buyback and LTIP, and balance reinvestment
for growth with the medium-term objective of achieving an EBITDA margin of 40–45
per cent.

[q2-2026-interim-report-english](https://www.directorstalkinterviews.com/wp-content/uploads/2026/08/q2-2026-interim-report-english.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/08/q2-2026-interim-report-english.pdf)

Share on:
